Basel, November 24, 2025 — Sandoz has officially launched Afqlir® (aflibercept) across Europe, introducing a more affordable treatment option for patients living with serious retinal diseases that can lead to vision loss. The medicine, now available in the UK and set to roll out in major markets such as Germany and France, is approved for the same uses as the reference drug Eylea®.